Skip to main content
. 2019 Oct 12;10(6):2201–2217. doi: 10.1007/s13300-019-00699-8

Table 7.

Incidence of treatment-emergent adverse events related to hypoglycaemia in the pooled comparative ipragliflozin (50 mg) studies stratified by combination with insulin

No combination Insulin combinations Non-insulin combinations Overall
Ipragliflozin 50 mg Placebo Ipragliflozin 50 mg Placebo Ipragliflozin 50 mg Placebo Ipragliflozin 50 mg Placebo
Hypoglycaemia, n/N (%) 3/237 (1.3) 2/215 (0.9) 52/175 (29.7) 13/87 (14.9) 21/797 (2.6) 10/494 (2.0) 76/1209 (6.3) 25/796 (3.1)